Aurora Cannabis reported Q2 fiscal 2026 net revenue of C$90.4 million, an 11% year-over-year increase that surpassed analyst expectations, primarily driven by a 15% surge in global medical cannabis sales. This growth, alongside a 52% rise in adjusted EBITDA, underscores the company's successful strategic shift towards the higher-margin medical segment, despite a 34% decline in consumer cannabis revenue. Looking ahead, Aurora anticipates continued consolidated revenue growth in Q3, fueled by an 8-12% expansion in medical cannabis, and expects to achieve positive free cash flow.
Aurora Cannabis reported robust Q2 fiscal 2026 results, with net revenue climbing 11% year-over-year to C$90.4 million, surpassing analyst expectations of C$87.33 million. This outperformance was primarily fueled by a significant 15% increase in global medical cannabis sales, underscoring the segment's strong growth trajectory. The company's strategic pivot towards higher-margin medical cannabis is evident in these results, despite a 34% decline in consumer cannabis revenue to C$6.9 million. This focus contributed to a substantial 52% rise in adjusted EBITDA, indicating improved operational efficiency and profitability from its core business. Looking ahead, Aurora Cannabis projects continued consolidated net revenue growth for Q3, driven by an anticipated 8% to 12% expansion in its Global Medical Cannabis segment. Crucially, the company also expects to achieve positive free cash flow for the period, signaling a move towards sustainable financial health.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment
